- Romania
- /
- Food and Staples Retail
- /
- BVB:RMAH
Farmaceutica REMEDIA Second Quarter 2024 Earnings: RON0.01 loss per share (vs RON0.02 profit in 2Q 2023)
Farmaceutica REMEDIA (BVB:RMAH) Second Quarter 2024 Results
Key Financial Results
- Revenue: RON181.9m (up 22% from 2Q 2023).
- Net loss: RON1.23m (down by 165% from RON1.91m profit in 2Q 2023).
- RON0.01 loss per share (down from RON0.02 profit in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Farmaceutica REMEDIA's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 5 warning signs for Farmaceutica REMEDIA (1 doesn't sit too well with us!) that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BVB:RMAH
Flawless balance sheet moderate.